Passive immunization for the prevention of otitis media

Vaccine

Volumn 19, Issue SUPPL. 1, 2000, Pages

  Englund, Janet A ^a   Glezen, W Paul ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Maternal immunization; Otitis media; Passive immunization; Respiratory syncytial virus; Streptococcus pneumoniae; Vaccines

Indexed keywords

BACTERIAL POLYSACCHARIDE IMMUNE GLOBULIN; BACTERIUM ANTIBODY; EPITOPE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HYPERIMMUNE GLOBULIN; INFLUENZA VACCINE; MATERNAL ANTIBODY; PALIVIZUMAB; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PURIFIED FUSION PROTEIN 2; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TETANUS TOXOID; TRIPLE VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TARGETING; HAEMOPHILUS INFLUENZAE TYPE B; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; NEWBORN INFECTION; OTITIS MEDIA; PASSIVE IMMUNIZATION; PLACENTAL TRANSFER; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

EID: 0034623921     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00289-9     Document Type: Short Survey

References (44)

1. Antibiotic-resistant Streptococcus pneumoniae in acute otitis media: Overview and update
2. The promise of immunoprophylaxis for prevention of acute otitis media
3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants
4. Advances in pneumococcal vaccines
5. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children
6. Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: Report of a pilot study
7. Efficacy and pharmacokinetics of intravenous immune globulin administration to high-risk neonates
8. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates
9. Intravenous immunoglobulin (IVIG) prophylaxis of late-onset septicemia in neonates
10. For the NICHD Neonatal Research Network. A controlled trial of intravenous immunoglobulin to reduce nosocomial infections in very-low-birthweight infants
11. Evaluation of an intravenous immunoglobulin preparation for the prevention of viral infection among hospitalized low birth weight infants
12. Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ count of 0.20×109 or more: Effect on viral, opportunistic, and bacterial infections
13. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children
14. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: A randomized, controlled clinical trial
15. Intravenous immunoglobulin use in the neonate: Role in prophylaxis and therapy of infection
16. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin
17. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children
18. Prophylaxis with high-titer respiratory syncytial virus immune globulin in high-risk children
19. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis
20. Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children
21. Safety and respiratory virus antibody levels in pediatric bone marrow transplant/stem cell recipients (BMT) receiving high-titered respiratory syncytial virus immunoglobulin (RSVIG)
22. Maternal immunization against viral disease
23. Maternal immunization for the prevention of infections in late pregnancy and early infancy
24. Effectiveness of prenatal tetanus toxoid immunization against neonatal tetanus in a rural area in India
25. Maternal immunization with influenza or tetantus toxoid vaccine for passive antibody protection in young infants
26. Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy
27. Effect of maternal immunization with oral poliovirus vaccine on neonatal immunity
28. Oral polio vaccination during pregnancy: No increase in the occurrence of congenital malformations
29. Immunization of pregnant women with influenza A/New Jersey/76 virus vaccine: Reactogenicity and immunogenicity in mother and infant
30. Maternal immunization with the capsular polysaccharide vaccine for Haemophilus influenzae type b
31. Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines
32. Serum, breast milk, and infant antibody after maternal immunisation and pneumococcal vaccine
33. Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy
34. An epidemiologic approach to pneumococcal disease
35. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus
36. Prevention and control of influenza
37. Maternal immunization
38. Passive protection against respiratory syncytial virus disease in infants: The role of maternal antibody
39. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): The Western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection
40. IgG and IgA antibody in breast milk following postpartum immunization with RSV purified fusion protein vaccine (PFP-2) or trivalent inactivated influenza virus vaccine (TIV)
41. Maternal immunizaion with pneumococcal polysaccharide vaccine during the third trimester of pregnancy
42. Effect of third trimester maternal immunization with H. influenzae type b conjugate vaccine (HbOC) in the infant's response to primary immunization
43. A modified Farr assay is more specific than ELISA for measuring antibodies to Streptococcus pneumoniae capsular polysaccharides
44. Human milk secretory IgA antibody to nontypeable Haemophilus influenzae: Possible protective effects against nasopharyngeal colonization